New material to designed to surpass the efficacy of minoxidil

MIAMI BEACH, Fla., Aug. 23, 2011 /PRNewswire/ -- Biotechnology leader Divine Skin Inc. (DSKX) posted its highest quarterly revenue, $2.33 million, in the second quarter. The expanding innovator of personal care solutions credits recent investments in production for clearing backorders and accelerating sales, which are 79 percent ahead of the same period in 2010.

"One of our challenges has been keeping up with demand," said Divine Skin CEO Daniel Khesin. "We have invested significant resources into setting up a more robust operations platform. Now we have the right people in the right jobs managing the right plans for procurement, manufacturing, and accounting infrastructure. We will therefore continue to scale up to much more impressive numbers."

Divine Skin maintains a core focus on biotechnology development while building its consumer goods business. It's ongoing clinical studies for topical therapies have helped identify new molecules and many proprietary technologies in the treatment of common skin conditions such as alopecia. Recently the company has announced the launch of Nanoxidil, a new material to designed to surpass the efficacy of minoxidil. This kind of innovations within personal care is expected to maintain Divine Skin's position as a category leader in niche categories and drive strong revenue growth.

"At the heart of this business is the relentless drive for innovation of personal care products," commented Khesin. "Every day we are only getting better at what we do and creativity is reaching new horizons. Customers and shareholders should prepare for very exciting things to come," he added.

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.